Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Ziopharm Oncology (Nasdaq: ZIOP) held its annual shareholder meeting on May 19, 2021, where all proposed measures were approved. Interim CEO Heidi Hagen highlighted progress and a commitment to shareholder value, discussing the company's key investigational therapies, including CD19 RPM CAR-T and TCR-T Library therapies. Shareholders supported plans to increase authorized shares for capital strategies. Hagen emphasized the need for affordable cancer therapies, aiming to make treatments accessible in local hospitals. The company's strategy aims to transform their cancer treatment approach.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) announced its Q1 2021 financial results and key updates on May 6, 2021. The company reported a net loss of $21.6 million, or $(0.10) per share, compared to a net loss of $18.3 million, or $(0.09) per share, in Q1 2020. R&D expenses increased to $13.3 million, driven by cell therapy program costs. Significant milestones included the first patient infusion in a CAR-T trial in Taiwan and the completion of a GMP facility in Houston. The annual shareholder meeting is scheduled for May 19, 2021.
Key Participation at Cellicon Valley Symposium
BOSTON, May 04, 2021 – Ziopharm Oncology (Nasdaq: ZIOP) announced that Dr. Laurence J.N. Cooper will participate in a panel discussion at the University of Pennsylvania’s Cellicon Valley symposium on May 6-7, 2021. Dr. Cooper will focus on Ziopharm's cellular therapy technologies for solid tumors, highlighting the proprietary Sleeping Beauty gene transfer system. The session will be moderated by Dr. Fyodor D. Urnov and will include a live Q&A on May 6 at 3:30 PM ET.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) will report its first quarter 2021 financial results on May 6, 2021, followed by a conference call at 4:30 p.m. EDT. The annual shareholder meeting is scheduled for May 19, 2021, at 9:00 a.m. EDT, to be held virtually. Shareholders can attend the meeting and participate by voting and submitting questions online. Ziopharm specializes in developing non-viral and cytokine-driven cell and gene therapies to treat cancer. More details can be accessed on their website.
Ziopharm Oncology recently showcased its innovative cellular therapy technologies at Aldevron's Virtual Breakthrough Speaker Series, with Dr. Laurence J.N. Cooper presenting. The presentation highlighted the company's proprietary non-viral gene transfer system, Sleeping Beauty, which addresses significant needs in cancer treatment. Dr. Cooper emphasized the commercial potential in hematological and epithelial solid tumors. Ziopharm is recognized as a leader in the cellular therapy sector, collaborating with top institutions to advance its cost-effective T-cell therapies.
Ziopharm Oncology, Inc. has initiated its CD19-Specific Rapid Personalized Manufacturing CAR-T Phase I Trial, with the first patient infused at National Taiwan University Hospital. This trial, conducted by Eden BioCell in collaboration with TriArm Therapeutics, aims to evaluate the safety of genetically engineered T cells produced via the Sleeping Beauty transposon system. Up to 24 patients suffering from relapsed CD19+ leukemias and lymphomas will be enrolled. The primary goal is to assess the tolerability of the RPM process.
Ziopharm Oncology announced its participation in the AACR Virtual 2021 Annual Meeting with a poster presentation focused on non-viral TCR-T therapies for epithelial cancers. The study utilizes the Sleeping Beauty transposon system to enhance T cell specificity against p53 and KRAS neoantigens. The findings support the development of stable, engineered TCR-T cell populations targeting these common mutations. Dr. Raffaele Baffa expressed optimism regarding the scientific rationale backing their Phase I/II clinical study for the TCR-T Library.
Ziopharm Oncology has appointed Heidi Hagen as Interim Chief Executive Officer, succeeding Dr. Laurence Cooper, who will remain in a scientific advisory role. The company announced FDA IND clearance for its Library TCR-T Phase I/II clinical trial targeting six KRAS and TP53 mutations. Financially, the company reported a net loss of $22.8 million for Q4 2020, compared to $15.7 million in Q4 2019. Full-year losses were $80 million, down from $117.8 million the previous year. The company has $115.1 million in cash to fund operations into Q2 2022.
Ziopharm Oncology (Nasdaq: ZIOP) announced a conference call on February 25, 2021, at 4:30 PM EDT to discuss its Q4 and full year 2020 financial results. Investors can access the call by dialing the provided numbers or via the company’s website. Additionally, an R&D Day is scheduled for March 11, 2021, at 11:00 AM EDT, where further details will be shared. Ziopharm is focused on developing non-viral cell and gene therapies to enhance cancer treatment, leveraging collaborations with key research institutions.
Ziopharm Oncology has elected Robert Postma to its Board of Directors, effective immediately. Postma, founder of WaterMill Asset Management, is a significant shareholder in Ziopharm. Board Chairman James Huang expressed confidence in Postma's financial expertise contributing to the company's promising T-cell directed and cytokine technologies. CEO Laurence Cooper noted the added shareholder guidance would positively impact strategic direction. This change expands the board from eight to nine members, signaling a commitment to enhancing governance.
